Skip to content

Non-Small Cell Lung Cancer (NSCLC) Needs Assessment Survey

Please complete the following survey to help us better understand learning needs among medical oncologists/oncology pharmacists who specialize in lung cancer diagnosis and management. Your feedback will help in the development of future HCP-led learning programs.

In appreciation of your time and effort, the first 25 respondents will be eligible to receive a $100 gift-o-gram, delivered to you electronically by providing your name and email address. This information will be used for the sole purpose of delivering compensation.

This survey is sponsored by Regeneron Canada, who will receive aggregated, non-identifiable results. No personally identifiable information will be shared with the sponsor.
Section 1: Practice-Related Questions
1.In which Canadian province or territory do you practice?(Required.)
2.Where do you work?(Required.)
3.What is your profession?(Required.)
4.How many years have you been in practice?(Required.)
5.In the last 12 months, what proportion of patients in your practice had a diagnosis of non-small cell lung cancer (NSCLC)?(Required.)
6.What proportion of your NSCLC patients were advanced (stage 3B/C)/metastatic?(Required.)
Section 2: Current Proficiency Level – Content
7.Please rate your current level of knowledge on the following topics related to advanced NSCLC without actionable genomic alterations:(Required.)
5 - Very High
4 - High
3 - Neutral
2 - Low
1 - Very Low
Disease features, epidemiology, prognosis
Diagnosis and staging
Biomarker testing
Treatment guidelines
Non-pharmacological treatment modalities (e.g., surgery, radiation)
Targeted therapy options
Immunotherapy options
Clinical trial data of available treatment options
Clinical trial data of emerging treatment options
Real-world evidence
Health Canada indications of systemic therapies
Supportive care
Quality of life data
Identification of patients with locally advanced NSCLC that are not candidates for surgical resection or definitive chemoradiation
Management of patients in the adjuvant setting
Management of patients in the 1L metastatic setting
Management of patients in the 2L metastatic setting
Retreatment of patients with immunotherapy + chemotherapy following progression on immunotherapy
Management of patients beyond the 2L metastatic setting
Management of patients with brain metastases
Management of patients with poor performance status
Management of patients based on squamous or non-squamous histology
Management of patients based on PD-L1 expression level
Identification of patients with NSCLC eligible for immunotherapy
Recognition of immune-mediated adverse events
Management of immune-mediated adverse events
Patient/caregiver counselling
Integration of quality of life and patient preference considerations into treatment decision making
Section 3: Future Learning Initiatives – Content
8.To guide the content of future learning initiatives focused on the management of advanced NSCLC without actionable genomic alterations, please rate your level of interest in improving/strengthening your knowledge/skills on the following topics:(Required.)
5 - Very High
4 - High
3 - Neutral
2 - Low
1 - Very Low
Disease features, epidemiology, prognosis
Diagnosis and staging
Biomarker testing
Treatment guidelines
Non-pharmacological treatment modalities (e.g., surgery, radiation)
Targeted therapy options
Immunotherapy options
Clinical trial data of available treatment options
Clinical trial data of emerging treatment options
Real-world evidence
Health Canada indications of systemic therapies
Supportive care
Quality of life data
Management of patients in the adjuvant setting
Management of patients in the 1L metastatic setting
Management of patients in the 2L metastatic setting
Retreatment of patients with immunotherapy + chemotherapy following progression on immunotherapy
Management of patients beyond 2L metastatic setting
Management of patients with brain metastases
Management of patients with poor performance status
Management of patients based on squamous or non-squamous histology
Management of patients based on PD-L1 expression level
Identification of patients with NSCLC eligible for immunotherapy
Identification of patients with locally advanced NSCLC that are not candidates for surgical resection or definitive chemoradiation
Identification of immune-mediated adverse events
Management of immune-mediated adverse events
Patient/caregiver counseling
Integration of quality of life and patient preference considerations into treatment decision making
Collaboration with members of the multidisciplinary team
Management of patients in remote/rural communities
9.What important knowledge gaps related to advanced NSCLC management should be addressed in future learning initiatives?(Required.)
10.What important clinical challenges related to advanced NSCLC management should be addressed in future learning initiatives?(Required.)
11.What other healthcare professionals involved in NSCLC management could also benefit from additional learning programs? Please check all that apply.(Required.)
Section 4: Future Learning Initiatives – Format
12.Please rate your level of interest in the following learning program formats:(Required.)
5 - Very High
4 - High
3 - Neutral
2 - Low
1 - Very Low
Conference symposium
Accredited learning program
Non-accredited learning program
Live webinar
On-demand video
Speaker tour
Self-guided study program
Podcast
Other program format (please specify below)
13.Please rate the following components in terms of their level of importance in an effective learning program:(Required.)
5 - Very High
4 - High
3 - Neutral
2 - Low
1 - Very Low
Case-based learning
In-person programs
Virtual/digital programs
Group discussions
Expert panel
Debate
Printable/digital materials (workbook/guides)
Modular content (e.g., 20-30 minutes per module)
Video/audio elements
Customizability
Gamified format
Other component (please specify below)
14.Please indicate your level of interest in the following formats for post-conference coverage:(Required.)
5 - Very High
4 - High
3 - Neutral
2 - Low
1 - Very Low
Live in-person small group discussion
Top abstracts summary sheet
Email/newsletter
Webinar
On-demand video
Podcast
Other format (please specify below)
15.What is the ideal length of time for a group learning program?(Required.)
16.What is the preferred time of day for a group learning program?(Required.)
17.Any other comments or suggestions on specific learning needs, format, speakers, etc.?
Please provide your name and email address if you wish to be eligible to receive a $100 gift-o-gram.
18.Name:
19.Email address:
Thank you for completing the survey!